Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129961 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1604337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commentary: Guselkumab binding to CD64 IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.
Front Immunol
May 2025
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Guselkumab in the IL-23 inhibition landscape for ulcerative colitis.
Lancet
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
JAMA Dermatol
September 2024
Department of Dermatology, and Interdisciplinary Center for Inflammatory Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Importance: Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies.
Objective: To evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis.
Design, Setting, And Participants: The GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis.
Oral Psoriasis Therapies.
Dermatol Clin
July 2024
Department of Dermatology, Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA; Department of Dermatology, Harvard Medical School, 3 Blackfan Cir, Boston, MA 02115, USA. Electronic address: clea
Oral psoriasis therapies include both older traditional immunosuppressants, such as methotrexate, cyclosporine, and acitretin, as well as newer, more targeted agents, such as apremilast, deucravacitinib, and oral interleukin-23 receptor antagonists. Patients may prefer oral therapies to injectable therapies based on the route of administration. Both older and newer oral psoriasis therapies can be utilized effectively in the treatment of psoriasis.
View Article and Find Full Text PDFPrior exposure to fumaric acid esters does not impact on subsequent treatment response to guselkumab.
Br J Dermatol
June 2024
Department of Dermatology, St. Vincent's University Hospital Dublin, Ireland.